Screening for Postpartum Thyroid Dysfunction in the General Population Is Beneficial

Nobuyuki Amino, Hisato Tada and Yoh Hidaka

Department of Laboratory Medicine, Osaka University Medical School, Osaka 565-0871, Japan


    Introduction
 Top
 Introduction
 There are effective protocols...
 The benefits of screening...
 There has been no...
 Conclusion
 References
 
POSTPARTUM thyroid dysfunction is recognized as a common disease among postpartum women (1), with a prevalence rate of around 5%, i.e. 1 in 20 pregnant women suffers from thyroid dysfunction after parturition (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14). To discuss whether screening for postpartum thyroid dysfunction is beneficial, we shall examine the following questions:

  1. Are there any effective tests or protocols to screen postpartum thyroid dysfunction?
  2. What is the benefit of the screening for postpartum thyroid dysfunction?
  3. Does the effectiveness meet the costs?


    There are effective protocols to screen postpartum thyroid dysfunction
 Top
 Introduction
 There are effective protocols...
 The benefits of screening...
 There has been no...
 Conclusion
 References
 
Postpartum autoimmune thyroid dysfunction is briefly characterized as a postpartum exacerbation of subclinical autoimmune thyroid disease, wherein some immunological abnormalities are observed before the onset of thyroid dysfunction. Therefore, we can detect the high-risk group for postpartum thyroid dysfunction by screening, in early pregnancy, those with subclinical autoimmune thyroiditis. Among several methods for detecting thyroid autoimmunities, the measurement of anti-thyroid microsomal antibody (MCAb) or thyroid peroxidase (TPO) antibody is the most useful marker for detecting subclinical autoimmune thyroiditis and, therefore, for predicting the occurrence of postpartum thyroid dysfunction. When MCAb is positive, there is always lymphocytic infiltration into the thyroid, indicating subclinical autoimmune thyroiditis (15) that may be exacerbated after delivery. Sixty to seventy percent of women with positive MCAb in early pregnancy develop postpartum thyroid dysfunction (1). Other investigators have also reported that MCAb-positive subjects had approximately 20–23 times the relative risk (over normal subjects) for developing postpartum thyroid dysfunction (16, 17). On the other hand, the prevalence of postpartum thyroid dysfunction in the MCAb-negative subjects in early pregnancy is estimated as 1/100 of that in MCAb-positive subjects (Fig. 1Go).So, when we screen 1000 early pregnant women in the general population, we can expect to find about 50 patients with postpartum thyroid dysfunction.



View larger version (29K):
[in this window]
[in a new window]
 
Figure 1. The prevalence of antithyroid MCAb and the occurrence of postpartum thyroid dysfunction among pregnant women in the general population.

 
Although MCAb is a good marker for the occurrence of postpartum thyroid dysfunction, it gives no information about the type of dysfunction that will occur. Among the various types of dysfunctions, postpartum Graves’ disease is clinically the most important and is predicted by the measurement of thyroid-stimulating antibodies (TSAb) with a sensitive bioassay (18). Our subsequent study (19) revealed that pregnant women with positive TSAb in early pregnancy had a much higher risk of developing postpartum Graves’ disease. We observed 71 pregnant women with positive MCAb from early pregnancy through the postpartum period. Among them, 7 showed positive TSAb, and 5 of those 7 (71%) developed postpartum Graves’ disease. Thyrotoxicosis in 3 of those 5 was transient and spontaneously improved within a year. Graves’ disease did not occur in the TSAb-negative subjects. Anti-TSH receptor (TSHR) antibodies (TRAb) with conventional radio-receptor assay (thyrotropin binding inhibitory immunoglobulin; TBII) were not useful in predicting postpartum Graves’ disease.

Figure 2sGohows a protocol that we have tentatively employed to screen for postpartum thyroid dysfunction at the outpatient maternity clinic of the Osaka University Hospital for several years. In the protocol, MCAb-positive mothers are examined for thyroid status, measuring serum free thyroxine (FT4), serum free triiodothyronine (FT3), serum thyrotropin (TSH), anti-TSHR antibody (TRAb), and antithyroglobulin (TgAb), and are observed every 4–8 weeks. We believe that this close observation protocol for MCAb-positive subjects is practical in only a few countries, such as Japan, where the national health insurance system is well-established. It should be modified according to the situation and health system of each country.



View larger version (32K):
[in this window]
[in a new window]
 
Figure 2. A protocol to screen and follow MCAb-positive mothers. MCAb, antithyroid microsomal antibody; FT4, free thyroxine; FT3, free triiodothyronine; TSH, thyrotropin; TRAb, anti-TSH receptor antibody.

 

    The benefits of screening postpartum thyroid dysfunction
 Top
 Introduction
 There are effective protocols...
 The benefits of screening...
 There has been no...
 Conclusion
 References
 
Although postpartum thyroid dysfunction may be transient in many cases (20), we should pay close attention to the possibility that mothers with thyroid dysfunction already tired from the birth and from taking care of a newborn, may feel terribly worn out and helpless or may become ill in bed. Postpartum depression, which in severe cases may result in a forced double suicide of mother and baby (called "Shinjuh" in Japanese), can be screened by MCAb measurement, although postpartum depression may occur not in association with thyroid dysfunction (17, 21, 22, 23) but with antithyroid MCAb (24, 25). The main benefit of screening for postpartum thyroid dysfunction is the opportunity to improve the quality of life of mothers who may suffer from the above symptoms. Even when the patient does not want drug therapy, she benefits by being informed about what is happening to her. From our experience, patients with mild to moderate thyroid dysfunction can live well with the support of family without medication. Further, prevention of future episodes of postpartum thyroid dysfunction may be possible. We have experienced one case of successful prevention. The patient had developed severe postpartum thyroid dysfunction in each of her previous parturitions, and she did not want to repeat the condition after the next delivery. Moderate doses of glucocorticoid, gradually decreased and stopped in one month, suppressed her thyroid dysfunction to only a small fluctuation within the normal range.

Postpartum Graves’ disease accounts for 11.4% of postpartum thyroid dysfunctions (occurring in 0.54% of all mothers in the general population) (19). Conversely, 40% of Graves’ patients 20–39 yr old, who have had one or more deliveries, developed their disease during the postpartum period (26). Diagnosis of postpartum Graves’ disease early, while it is mild, may easily lead to remission and may reduce Graves’ disease in older age. In our experience, the early start of antithyroid therapy reduces the period of therapy by half (19). Antithyroid therapy may be a good choice for first-line therapy (27) because postpartum Graves’ hyperthyroidism is often transient and because mothers may not want to interrupt breast-feeding to undergo radioiodine therapy.

An additional benefit to screening with anti-MCAb antibodies in early pregnancy may be not only to find postpartum thyroid dysfunction, but also to find mothers at high risk for spontaneous abortion. In our prospective study, the spontaneous abortion rate in MCAb-positive mothers was twice as high as that in MCAb-negative mothers (28).


    There has been no analysis of the cost-effectiveness of screening for postpartum thyroid dysfunction
 Top
 Introduction
 There are effective protocols...
 The benefits of screening...
 There has been no...
 Conclusion
 References
 
The cost of MCAb measurement to screen for the occurrence of postpartum thyroid dysfunction is low when we use semiquantitative particle agglutination tests. However, thyroid function tests and anti-TSHR antibody measurement for MCAb-positive subjects are not cheap, especially when patients are observed closely and are tested repeatedly. On the other hand, the main benefit of screening for postpartum thyroid dysfunction is improving the mother’s quality of life, which is difficult to numerically assess. Heyslip et al. (29) tried to estimate the costs of several screening methods and concluded that MCAb measurement is the most cost-effective, but their report compares only the screening methods for postpartum thyroid dysfunction; they did not analyze the benefit of mothers’ quality of life, nor did they discuss cost-effectiveness compared with the screening for other diseases or other health services. Indeed, there seems no analysis of the cost-effectiveness of screening for postpartum thyroid dysfunction (23, 30). However, the observation protocol we describe can be modified to be less expensive, and screening subjects may be restricted to certain high-risk groups, such as the patients with IDDM. We believe an optimized system of screening will be found whose costs are acceptable for each society.

We experimentally applied TSAb to the second-line screening of MCAb-positive mothers and found that TSAb gives predictive information on potential development of postpartum Graves’ disease. TSAb measurement is obviously too expensive, and the procedure is too complicated to apply screening to the general population. However, we expect the development of a more sensitive radioreceptor assay may change the situation (31).


    Conclusion
 Top
 Introduction
 There are effective protocols...
 The benefits of screening...
 There has been no...
 Conclusion
 References
 
The benefit of screening for postpartum thyroid dysfunction mainly concerns elusive, nonquantitative parameters—the quality of life of mothers—that can be difficult to assess. However, we would hope to find an acceptable, cost-effective system of screening for postpartum thyroid dysfunction.


    Footnotes
 
Address correspondence and requests for reprints to: Alex Stagnaro-Green, MD, Dean for Student Affairs and Medical Education, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1255, New York, New York 10029-6574.

Accepted March 8, 1999.


    References
 Top
 Introduction
 There are effective protocols...
 The benefits of screening...
 There has been no...
 Conclusion
 References
 

  1. Amino N, Tada H, Hidaka Y. 1996 Autoimmune thyroid disease and pregnancy. J Endocrinol Invest. 19:59–70[Medline]
  2. Amino N, Mori H, Iwatani Y, et al. 1982 High prevalence of transient postpartum thyrotoxicosis and hypothyroidism. N Engl J Med. 306:849–852.[Medline]
  3. Jansson R, Bernander S, Karlsson A, Levin K, Nilsson G. 1984 Autoimmune thyroid dysfunction in the postpartum period. J Clin Endocrinol Metab. 58:681–687.[Abstract]
  4. Walfish P, Chan J. 1985 Postpartum hyperthyroidism. Clin Endocrinol Metab. 14:417–447.[Medline]
  5. Freeman R, Rosen H, Thysen B. 1986 Incidence of thyroid dysfunction in an unselected postpartum population. Arch Intern Med. 146:1361–1364.[Abstract]
  6. Nikolai TF, Turney SL, Roberts RC. 1987 Postpartum lymphocytic thyroiditis. Prevalence, clinical course, and long-term follow-up. Arch Intern Med. 147:221–224.[Abstract]
  7. Lervang HH, Pryds O, Kristensen HP. 1987 Thyroid dysfunction after delivery: incidence and clinical course. Acta Med Scand. 222:369–374.[Medline]
  8. Fung HYM, Kologlu M, Collison K, et al. 1988 Postpartum thyroid dysfunction in Mid Glamorgan. Br Med J. 296:241–244.[Medline]
  9. Rasmussen NG, Hornnes PJ, Hoiter-Madsen M, Feldt-Rasmussen U, Hegedus L. 1990 Thyroid size and function in healthy pregnant women with thyroid autoantibodies. Acta Endocrinol (Copenh). 123:395–401.[Medline]
  10. Rajatanavin R, Chailurkit LO, Tirarungsikul K, Chalayondeja W, Jittivanich U, Puapradit W. 1990 Postpartum thyroid dysfunction in Bangkok: a geographical variation in the prevalence. Acta Endocrinol (Copenh). 122:283–287.[Medline]
  11. Roti E, Bianconi L, Gardini E, et al. 1991 Postpartum thyroid dysfunction in an Italian population residing in an area of mild iodine deficiency. J Endocrinol Invest. 14:669–674.[Medline]
  12. Löbig H, Bohn W, Mau J, Schatz H. 1991 Prevalence of postpartum thyroiditis in two iodine-deficient regions of Germany. In: Scherbaum W, Bogner U, Weinheimer B, and Bottazzo G, eds. Autoimmune thyroiditis. Berlin: Springer-Verlag; 185–193.
  13. Walfish PG, Meyerson J, Provias JP, Vargas MT, Papsis FR. 1992 Prevalence and characteristics of post-partum thyroid dysfunction: Results of a survey from Toronto, Canada. J Endocrinol Invest. 15:265–272.[Medline]
  14. Stagnaro-Green A, Roman SH, Cobin RH, el-Harazy E, Wallenstein S, Davies TF. 1992 A prospective study of lymphocyte-initiated immunosuppression in normal pregnancy: evidence of a T-cell etiology for postpartum thyroid dysfunction. J Clin Endocrinol Metab. 74:645–653.[Abstract]
  15. Yoshida H, Amino N, Yagawa K, et al. 1978 Association of serum antithyroid antibodies with lymphocytic infiltration of the thyroid gland: studies of seventy autopsied cases. J Clin Endocrinol Metab. 46:859–862.[Abstract]
  16. Solomon BL, Fein HG, Smallridge RC. 1993 Usefulness of antimicrosomal antibody titers in the diagnosis and treatment of postpartum thyroiditis. J Fam Pract. 36:177–182.[Medline]
  17. Pop VJM, de Rooy HA, Vader HL, van der Heide D, van Son MM, Komproe IH. 1993 Microsomal antibodies during gestation in relation to postpartum thyroid dysfunction and depression. Acta Endocrinol (Copenh). 129:26–30.[Medline]
  18. Tamaki H, Amino N, Aozasa M, Mori M, Tanazawa O, Miyai K. 1987 Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves’ disease. J Clin Endocrinol Metab. 65:324–330.[Abstract]
  19. Hidaka Y, Tamaki H, Iwatani Y, Tada H, Mitsuda N, Amino N. 1994 Prediction of postpartum onset of Graves’ thyrotoxicosis by measurement of thyroid stimulating antibody in early pregnancy. Clin Endocrinol (Oxf). 41:15–20.[Medline]
  20. Amino N, Tada H, Hidaka Y. 1996 The spectrum of postpartum thyroid dysfunction: diagnosis, management, and long-term prognosis. Endocr Pract. 2:406–410.
  21. Harris B, Fung H, Johns S, et al. 1989 Transient postpartum thyroid dysfunction and postnatal depression. J Affect Disord. 17:243–249.[CrossRef][Medline]
  22. Pop VJM, Rooy HAM, Vader HL, et al. 1991 Postpartum thyroid dysfunction and depression in an unselected population. New Engl J Med. 324:1815–1816.[Medline]
  23. Lazarus JH, Harris B, Parkes AB. 1996 Antenatal screening of thyroid antibodies. Lancet. 348:1516–1517.
  24. Harris B, Othman S, Davies JA, et al. 1992 Association between postpartum thyroid dysfunction and thyroid antibodies and depression. BMJ. 305:152–156.[Medline]
  25. Pop VJ, Maartens LH, Leusink G, et al. 1998 Are autoimmune thyroid dysfunction and depression related? J Clin Endocrinol Metab. 83:3194–3197.[Abstract/Free Full Text]
  26. Tada H, Hidaka Y, Itoh E, et al. 1994 Prevalence of postpartum onset of disease within patients with Graves’ disease of child-bearing age. Endocr J. 41:325–327.[Medline]
  27. Amino N, Tada H. 1997 Postpartum thyroid disease. In: Bardin CW, ed. Current therapy in endocrinology and metabolism, 6th ed. Philadelphia: Mosby-Year Book, Inc.; 327–330.
  28. Iijama T, Tada H, Hidaka Y, Mitsuda N, Murata Y, Amino N. 1997 Effects of autoantibodies on the course of pregnancy and fatal growth. Obstet Gynecol. 90:364–369.[Abstract/Free Full Text]
  29. Haylip CC, Fein HG, O’Donnel VM, et al. 1988 The value of serum antimicrosomal antibody testing in screening for symptomatic postpartum thyroid dysfunction. Am J Obstet Gynecol. 159:203–209.[Medline]
  30. Ball S. 1996 Antenatal screening of thyroid antibodies. Lancet. 348:906–907.[Medline]
  31. Watabnabe Y, Tada H, Hidaka Y, et al. 1999 Polyethylene glycol increases the detection of anti-thyrotropin (TSH) receptor antibodies by a radioreceptor assay. Clin Chem. 45:407–409.[Free Full Text]